Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABBOTT PARK, Ill., Nov. 16, 2020 /PRNewswire/ -- For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability. As the Global...

Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)

Danaher

Estee Lauder

Johnson & Johnson

Coca-Cola

McDonald's

Mondelez

PepsiCo

Procter & Gamble

Walmart

In this article we present the list of Top 10 Stocks Billionaire Ray Dalio Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire Ray Dalio Just Bought .

Top 10 Stocks Billionaire Ray Dalio Just Bought

Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.

Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.

Baxter

ResMed

3 Stocks to Capitalize on Promising Medical Products Industry

Moderna

Novavax

These companies are working on drug catalysts that could fuel massive expansion.

3 Coronavirus Stocks With Long-Term Growth Potential

Gilead Sciences

These stocks have been going in opposite directions of late.

Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?

Medical company Abbott has now launched a handful of coronavirus tests, and the U.S. is paying $750 million for 150 million of one of its recently approved tests. So, is ABT stock a buy now?

Abbott Tacks On Massive Coronavirus Test Growth — But Is ABT Stock A Buy?

QuidelOrtho Corp

Quest Diagnostics

Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period. Covid-19 testing stocks could be.

Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge

Abbott's stock lost more than 27% – dropping from $87 at the beginning of the year to below $63 in late March – then spiked 66% to around $105 now. That means it is well above the levels where it started the year.

Continue To Ride Abbott Stock In The Current Pandemic

This company is already generating revenue from its coronavirus projects.

Forget Moderna -- This Is A More Lucrative Coronavirus Stock

Abbott is one of the stock market's steadiest performers. COVID-19 opens the door for realizing the vision underlying the Alere acquisition.

Abbott: Ballast Your Portfolio For Uncertain Times

LONDON--(BUSINESS WIRE)-- #CoronavirusTestKitsMarketinEurope--The Coronavirus Test Kits Market in Europe will grow by $ -139.05 mn during 2020-2024

Global Coronavirus Test Kit Market in Europe- Featuring 3D Biomedicine Science and Technology Co. Ltd., Abbott Laboratories, and BGI Genomics Co. Ltd.

Netflix

Adding shares of these companies to your portfolio during a market crash would be a much better move than panic selling.

2 No-Brainer Stocks to Buy In The Next Market Crash

Anheuser-Busch InBev

H&R Block

Kroger

NextEra Energy

Sturm, Ruger & Company

Vista Outdoor

No matter who wins the presidential election, the results will be jarring to millions of Americans. Prepare yourself early by getting into these companies to invest in before 2021.

9 Companies to Invest In Before We Hit 2021

NVIDIA

Visa

The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share grow by approximately 4% on average every year over the past five years. The share price of the benchmark for the U.S. stock market ($3,400.97 as of Monday) has gained nearly 65% over the past five years through Oct. 26.

A Trio of Stocks Growing Revenue Per Share

Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Abbott (ABT) Stock

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Global Growth Composite Portfolio returned 9.09% gross of fees, while the MSCI All Country World Index was up 8.14%. You should check out Polen Capital's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Polen Capital is Betting on Abbott Laboratories (ABT) Stock

AstraZeneca

You can probably hold onto these winners beyond 2030.

Have $1,000? 2 Fantastic Coronavirus Stocks to Buy and Hold for the Next Decade

Abbott Laboratories (NYSE: ABT) reported strong third-quarter results Wednesday and looks able to generate double-digit earnings growth going ahead, even without considering testing revenue, according to BofA Securities. The Abbott Laboratories Analyst: Bob Hopkins reiterated a Buy rating on Abbott Laboratories with an unchanged $122 price target.

Abbott Laboratories Has 'Solid Upside Potential,' BofA Says After Q3 Print

Teladoc

The COVID-19 pandemic will likely get worse before it gets better. These two stocks could be safe havens for investors.

2 Stocks to Buy as the Third Coronavirus Wave Hits

Ford Motor Company

Abbott Laboratories (ABT) CEO Robert Ford on Q3 2020 Results - Earnings Call Transcript

Revenue and earnings beats were only part of the story.

Here's What to Really Like About Abbott Labs' Q3 Results

Abbott Laboratories (NYSE: ABT) published its earnings report for the fiscal third quarter on Wednesday. The company said that its earnings in Q3 came in stronger than what analysts had expected, and expressed confidence that its performance was likely to remain strong in the rest of the year.

Abbott Laboratories' sales jump 9.6% in the fiscal third quarter

In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.

Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

Thermo Fisher Scientific

Tesla

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.

News for Abbott Labs Stock (ABT)